AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02465359
Drug: Immune Globulin Subcutaneous (Human)
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
Trial: NCT00689156
Drug: Epirubicin, cyclophosphamide and docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
Trial: NCT00689156
Drug: docetaxel, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
Trial: NCT04774224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
Trial: NCT03027375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
Trial: NCT01657097
Drug: INCS
RxNorm normalized name: ZINC OXIDE 13 g in 100 mL TOPICAL LOTION [Zincscreen 100 Mineral SPF 40]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01657097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01921855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Trial: NCT03882905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet, oral, once daily
Trial: NCT03882905
Drug: Simivastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily administration at dose to be determined
Trial: NCT03882905
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
Trial: NCT02703324
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT00351910
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00891241
Drug: LMI 1195-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, bolus IV injection of LMI 1195
Trial: NCT01858766
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT00498589
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg per week IM or SC during 24 weeks
Trial: NCT00498589
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one intramuscular injection per week
Trial: NCT01979952
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily dosing
Trial: NCT01483183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose, 10-minute constant rate IV infusion
Trial: NCT02389036
Drug: SDD Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
Trial: NCT02389036
Drug: SDD Gastric Suspension
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
Trial: NCT02389036
Drug: Intravenous Antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
Trial: NCT00320021
Drug: Pyridorin (pyridoxamine dihydrochloride)
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02338622
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5363 BD
Trial: NCT00003512
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01683825
Drug: F-18 florbetapir PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
Trial: NCT04518540
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will take domestic riluzole tablets 50mg orally, twice a day.
Trial: NCT01379196
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tab. Azithromycin 500 mg PO three times weekly for 3 months
Trial: NCT00098579
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00269867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
Trial: NCT01919801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01638117
Drug: PAC14028-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC-14028 Cream, 0.1%, Daily for up to 21 days
Trial: NCT01638117
Drug: PAC14028-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC-14028 Cream, 0.3%, Daily for up to 21 days
Trial: NCT01638117
Drug: PAC14028-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC-14028 Cream, 1%, Daily for up to 21 days
Trial: NCT01843062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
Trial: NCT01185925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02365506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match tablets administered orally in a single dose
Trial: NCT01294683
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01294683
Drug: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01294683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00759330
Drug: Flurbiprofen Tape (Arm 2)
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Trial: NCT00759330
Drug: Placebo Tape (Arm 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
Trial: NCT00759330
Drug: Flurbiprofen Tape (Arm 4)
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Trial: NCT02470325
Drug: Avidekel oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avidekel cannabis oil 6:1 CBD:THC
Trial: NCT02470325
Drug: Enriched Avidekel oil
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched Avidekel cannabis oil 20:1 CBD:THC
Trial: NCT03067155
Drug: Standard anti-viral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue with the anti-viral treatment as per standard of care.
Trial: NCT01498588
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Trial: NCT01498588
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Trial: NCT02186665
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01907763
Drug: SOTB07 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01907763
Drug: SOTB07 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01907763
Drug: SOTB 200mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of SOTB07 200mg
Trial: NCT01907763
Drug: SOTB 400mg placebo
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of SOTB07 400mg
Trial: NCT00716846
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg, 2 weeks
Trial: NCT01251120
Drug: DMARD
RxNorm normalized name: Disease-modifying antirheumatic drug (DMARD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biologic DMARDs (including methotrexate) according to current best practice
Trial: NCT00628134
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single inhaled dose by nebulizer
Trial: NCT01524341
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAE609 was supplied as capsules for oral use.
Trial: NCT01227863
Drug: MAXINOM®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
Trial: NCT01227863
Drug: Maxitrol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
Trial: NCT01247194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral, once daily for 3 days
Trial: NCT03558256
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
Trial: NCT01387230
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5 mcg
Trial: NCT01387230
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mcg
Trial: NCT01807923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT02371603
Drug: GSK1278863 25 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
Trial: NCT02371603
Drug: Rosuvastatin 10 mg Tablet
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning
Trial: NCT01605981
Drug: AMN107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03854396
Drug: Prasterone
RxNorm normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
Trial: NCT02678416
Drug: IV Acetaminophen (Treatment A)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administered by intravenous (IV) infusion
Trial: NCT02678416
Drug: Oral Acetaminophen (Treatment B)
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administered by oral tablets
Trial: NCT02678416
Drug: Placebo (Treatment C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by IV infusion or oral tablets
Trial: NCT00195663
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00195663
Drug: Methotrexate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04659525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Trial: NCT04551950
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
Trial: NCT02639520
Drug: Canephron® N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets 3 times a day for 7 days
Trial: NCT02639520
Drug: Canephron® N-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets 3 times a day for 7 days
Trial: NCT02406105
Drug: CyberKnife
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03301298
Drug: SXC-2023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT03301298
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as oral capsule.
Trial: NCT03270332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation of placebo through a spacer
Trial: NCT02073734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given IV
Trial: NCT02451943
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02451943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00658463
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
Trial: NCT00658463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04666454
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion 70 µg/kg/min for 3 hours.
Trial: NCT01272947
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical gel 1%- 4 times daily
Trial: NCT02624778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04117009
Drug: Remifentanil 2 MG
RxNorm normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
Trial: NCT04445181
Drug: The physician's prescription in routine clinical practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an Observational study that will not involve prescription of the drugs.
Trial: NCT01180296
Drug: Identical Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
Trial: NCT03770780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with Ketamine
Trial: NCT01406977
Drug: BPS804
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03764345
Drug: Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
Trial: NCT01375361
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
Trial: NCT00388011
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo
Trial: NCT00093795
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Trial: NCT00093795
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles
Trial: NCT04173065
Drug: VK2809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04173065
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT00460551
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cisplatin and docetaxel administered as two cycles given every three weeks
Trial: NCT00606866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for four weeks
Trial: NCT01306331
Drug: Conceptrol
RxNorm normalized name: Conceptrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
Trial: NCT00680823
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
Trial: NCT03606837
Drug: 68Ga-PSMA-617 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT Imaging with 68Ga-PSMA-617 injection
Trial: NCT03606837
Drug: 68Ga-RM2 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT Imaging with 68Ga-RM2 injection
Trial: NCT04338828
Drug: Nitric Oxide Gas
RxNorm normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
Trial: NCT01211665
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
Trial: NCT04565249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04519281
Drug: IV of vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of high-dose of IV vitamin C perioperatively
Trial: NCT03152591
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 tablets for oral administration
Trial: NCT03152591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching LIK066 tablets, for oral administration